The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study (Q33480671)

27 July 2017

title

The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study (English)

1 reference

27 July 2017

0 references

1 reference

Linbo Wang

1 reference

27 July 2017

Zhinong Jiang

1 reference

27 July 2017

Meihua Sui

1 reference

27 July 2017

Jianguo Shen

1 reference

27 July 2017

Chaoyang Xu

1 reference

27 July 2017

Weimin Fan

1 reference

27 July 2017

language of work or name

English

0 references

publication date

11 July 2009

1 reference

27 July 2017

1 reference

27 July 2017

1 reference

27 July 2017

page(s)

226

1 reference

Creative Commons Attribution 2.0 Generic

27 July 2017

start time

11 July 2009

1 reference

April 2022 Public Data File from Crossref

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Triple negative breast cancer: current understanding of biology and treatment options

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Preoperative chemotherapy treatment of breast cancer--a review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor res

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Utilizing prognostic and predictive factors in breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Targeted therapy in breast cancer: the HER-2/neu gene and protein

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Prediction of response to hormonal treatment in metastatic breast cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Progesterone and the progesterone receptor.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Expression of genes implicated in multidrug resistance in acute lymphoblastic leukemia in India.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

The lack of relationship between estrogen receptor status and response to chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Estrogen receptors and breast cancer: prognostic and therapeutic implications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Tumour oestrogen receptor content allows selection of elderly patients with breast cancer for conservative tamoxifen treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Predicting Response to Endocrine Therapy in Human Breast Cancer: A Hypothesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-226

Does the degree of cell lesion in breast cancer after inductive chemotherapy have any prognostic value?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-226

Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-226

Physiological Action of Progesterone in Target Tissues*

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-226

HER2/neu expression in relation to clinicopathologic features of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-226

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-226

P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-226

Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716368

Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors

31 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-226

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer

21 January 2018

1 reference

12 December 2020

The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer

1 reference

12 December 2020

Assessment of biomarker expression in predicting pathologic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

1 reference

12 December 2020

p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients

1 reference

12 December 2020

Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome

1 reference

12 December 2020

Multidrug resistance and its reversal

1 reference

12 December 2020

The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer

1 reference

12 December 2020

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

12 December 2020

A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer

1 reference

12 December 2020

Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-9-226

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference